Suppr超能文献

血清肿瘤标志物在肺癌中的过去、现在和未来(液体活检):放射科医生的入门指南。

The Past, Present, and Future (Liquid Biopsy) of Serum Tumor Markers in Lung Cancer: A Primer for the Radiologist.

机构信息

From the Case Western Reserve University School of Medicine, Health Education Campus.

Departments of Radiology.

出版信息

J Comput Assist Tomogr. 2021;45(6):950-958. doi: 10.1097/RCT.0000000000001204.

Abstract

Lung cancer continues to be a major cause of death throughout the world. The ability to both accurately diagnose lung cancer in its early stages and monitor response to treatment is essential to reducing the morbidity and mortality associated with the disease. Serum tumor markers have been identified as potential biomarkers that may aid in lung cancer diagnosis and surveillance. These markers, when combined with cross-sectional imaging, may result in more robust screening and surveillance protocols. The future role of serum tumor markers in lung cancer includes the advancement of "liquid biopsies," in which peripheral blood samples are analyzed for tumor components without the need for a tissue biopsy.

摘要

肺癌仍然是全世界主要的死亡原因之一。能够准确诊断肺癌早期并监测治疗反应对于降低与该疾病相关的发病率和死亡率至关重要。血清肿瘤标志物已被确定为可能有助于肺癌诊断和监测的潜在生物标志物。这些标志物与横断面成像相结合,可能会产生更强大的筛查和监测方案。血清肿瘤标志物在肺癌中的未来作用包括“液体活检”的发展,即无需组织活检即可分析外周血样中的肿瘤成分。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验